Abstract
A meta-analysis of all Ph3 trials with CDKi plus endocrine therapy (ET) has established 13% incidence of LT of any grade (vs 5.4% with ET alone). However, the clinical characteristics of these pts and the predictive factors associated with developing LT remain unknown. All MBC pts treated with first-line CDKi in Vall d’Hebron Hospital from 2018 to 2022 were analyzed retrospectively. LT was defined as ≥G2 AST/ALT elevation. Clinical and laboratory characteristics, oncologic disease status, and evolution of liver function tests for those pts were registered. Among 472 pts treated, 26 (5.5%) developed LT, G2 in 11 (42%), G3 in 13 (50%) and G4 in 2(8%) without LT related-deaths. LT occurred in 3%, 8% and 11.6% of pts receiving palbociclib, abemaciclib and ribociclib, respectively. Baseline characteristics: median (M) age 61y, premenopausal 54%, overweight/obese 59%, 11.5% alcohol consumers, 27% current/former smokers, 27% stage IV de novo and 27% with liver metastases. As for cardiovascular risk factors: 32% had dyslipemia, 31% liver steatosis at CT scan and 26.9% arterial hypertension. Concomitant ET was letrozole 54%, fulvestrant 35% and anastrozole 11%. LT occurred after 7 cycles (M), and 218 days (IQR 37-399). Only 1 pt receiving abemaciclib had G4 bilirubin elevation without fulfilling Hy's Law criteria. In 88.5% LT returned to basal in 44 days (M) (IQR 26-61). CKDi was reintroduced in 58% of pts; 8% at the same dose, 54% at -1 dose level, and 38% at -2 dose level. Of them, 61.5% had a 2nd LT episode which resolved in 62.5% in 26 days (M) (IQR 14-49). The results by type of CDKi are shown in the table. Table: 250PCharacteristicsPalbociclibAbemaciclibRibociclibLT pts/Total pts8/2839/1129/77M days until LT1166398LT resolved87%75%100%M days to resolution282646Relapse of LT20%75%66%M days until relapse142011 Open table in a new tab In our cohort of pts 5.5% developed LT. LT reached G3 in 58% of cases, mainly with ribociclib. A high proportion of those pts had ≥25 BMI and 31% had liver steatosis. LT was mainly reversible with no fatal cases. These results could help to develop prediction scores to identify patients at risk of developing severe LT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.